Sunday 18 October 2026
Export CYTT’s income statement to Excel — free account
Cyteir Therapeutics, Inc.
CYTT Healthcare Biotechnology
Dividend growth for five consecutive years.
3.01
0.00
0.00%
Follow CYTT
Cyteir Therapeutics, Inc. (CYTT) P/E ratio
Cyteir Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (May 2024) to 0.0× (May 2024) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VANI Vivani Medical, Inc. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| GNLX Genelux Corporation compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| CYTT Cyteir Therapeutics, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)